CD8A and neoplasm: Since our in vitro data suggest that expansion with IL-2 over time compromises the anti-tumor activity of WT CD8 CAR-T cells (Fig. 3a, b), we tested the in vivo anti-tumor efficacy of WT and MCJ KO CD8 CAR-T cells that were expanded with IL-2 only for one expansion.